Author

Mihaela Talpes

Institution: Amgen (United States)

Observed institution: Amgen (United States)

ORCID: 0009-0004-6600-8838

Observed ORCID: 0009-0004-6600-8838

OpenAlex ID: A5098710912

EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma

2024 · Ola Landgren, Thomas J. Prior, et al. · Blood · 129

A phase 1/1b study of the BCMA-targeting bispecific T-cell engager pavurutamab for relapsed/refractory multiple myeloma

2026 · Hans C. Lee, Wouter J. Plattel, et al. · Blood · 3

Health-Related Quality of Life in Patients With Relapsed/Refractory Multiple Myeloma Treated With Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone: An Analysis of Patient-Reported Outcomes From the Phase 3 CANDOR Trial

2025 · Katja Weisel, Maria-Victoria Mateos, et al. · Clinical Lymphoma Myeloma & Leukemia · 3

Real-World Use of carfilzomib-lenalidomide-dexamethasone (KRd) and carfilzomib-dexamethasone (Kd) in Relapsed/Refractory Multiple Myeloma in the Asia Pacific Region: A Prospective Multicenter Observational Study

2025 · Hang Quach, Kihyun Kim, et al. · Clinical Lymphoma Myeloma & Leukemia · 1

Carfilzomib plus induction chemotherapy for children with relapsed or refractory acute lymphoblastic leukemia

2026 · Franco Locatelli, Musa Karakukcu, et al. · Blood Advances

Works count: 5

Citation count: 136

H-index: 3

I10-index: 1